# OnCo record paper-msb-gvhd001-bbmt-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-msb-gvhd001-bbmt-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-msb-gvhd001-bbmt-2020" ;
  schema:name "A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease"@en ;
  schema:description "The primary report of MSB-GVHD001: seven in ten children with steroid-refractory acute graft-versus-host disease responded to remestemcel-L by day 28, well above the 45 percent historical rate, and responders were far more likely to be alive at six months."@en ;
  schema:url <https://onco.cc/key-papers/paper-msb-gvhd001-bbmt-2020/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.bbmt.2020.01.018>, <https://pubmed.ncbi.nlm.nih.gov/32018062/>, <https://clinicaltrials.gov/study/NCT02336230> ;
  schema:sameAs <https://doi.org/10.1016/j.bbmt.2020.01.018> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Kurtzberg J, Abdel-Azim H, Carpenter P, et al." ;
  onco:drugs <https://onco.cc/drugs/remestemcel-l/> ;
  onco:companies <https://onco.cc/companies/mesoblast/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/allogeneic-transplant/> ;
  onco:trials <https://onco.cc/trials/msb-gvhd001/> .